Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$16.99 +1.9%	$17.67	$13.53 ▼ $35.25	$1.71B	2.08	1.49 million shs	1.84 million shs
GLPG Galapagos	$28.22 +1.1%	$27.17	$22.36 ▼ $31.23	N/A	0.07	248,299 shs	367,224 shs
HRMY Harmony Biosciences	$32.48 +0.0%	$32.47	$26.47 ▼ $41.61	$1.87B	0.87	626,648 shs	422,843 shs
SAGE Sage Therapeutics	$9.13 +0.1%	$7.16	$4.62 ▼ $13.47	$571.73M	0.18	1.28 million shs	2.87 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+1.92%	-5.03%	-3.79%	-25.71%	-26.67%
GLPG Galapagos	+1.07%	-0.46%	+1.11%	+9.72%	+9.21%
HRMY Harmony Biosciences	+0.03%	-7.57%	-9.55%	-6.93%	+12.43%
SAGE Sage Therapeutics	+0.11%	+34.86%	+29.14%	+13.98%	-15.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	3.2891 of 5 stars	4.5	1.0	0.0	2.7	2.5	0.6
GLPG Galapagos	0.2242 of 5 stars	0.8	2.0	0.0	1.4	0.0	0.6
HRMY Harmony Biosciences	4.7799 of 5 stars	4.6	1.0	0.0	3.5	3.3	4.4
SAGE Sage Therapeutics	3.0223 of 5 stars	2.0	1.0	4.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	186.93% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-10.23% Downside
HRMY Harmony Biosciences	3.11	Buy	$53.00	63.18% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.15% Downside

Current Analyst Ratings Breakdown

Latest SAGE, HRMY, BEAM, and GLPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	26.90	N/A	N/A	$8.86 per share	1.92
GLPG Galapagos	$298.31M	N/A	$0.73 per share	38.87	$47.57 per share	N/A
HRMY Harmony Biosciences	$714.73M	2.61	$2.95 per share	11.02	$11.56 per share	2.81
SAGE Sage Therapeutics	$41.24M	13.86	N/A	N/A	$7.60 per share	1.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	12.40	10.44	0.48	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)

Latest SAGE, HRMY, BEAM, and GLPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
GLPG Galapagos	N/A	7.95	7.86
HRMY Harmony Biosciences	0.22	3.67	3.63
SAGE Sage Therapeutics	N/A	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
GLPG Galapagos	32.46%
HRMY Harmony Biosciences	86.23%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
GLPG Galapagos	2.91%
HRMY Harmony Biosciences	23.60%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
GLPG Galapagos	1,310	N/A	N/A	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

SAGE, HRMY, BEAM, and GLPG Headlines

Recent News About These Companies

Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to Hold at Piper Sandler

June 19 at 3:31 AM | americanbankingnews.com

Truist Financial Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 19 at 3:31 AM | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright

June 19 at 2:48 AM | americanbankingnews.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18 at 11:03 PM | businesswire.com

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

June 18 at 7:01 PM | biospace.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $8.50 at Canaccord Genuity Group

June 18 at 3:23 AM | americanbankingnews.com

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

June 17 at 3:41 PM | zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

June 17 at 12:10 PM | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from Piper Sandler

June 17 at 11:36 AM | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $9.00

June 17 at 10:56 AM | marketbeat.com

HC Wainwright Reaffirms "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE)

June 17 at 10:37 AM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

June 17 at 10:00 AM | accessnewswire.com

Sage Therapeutics (NASDAQ:SAGE) Given New $8.50 Price Target at Canaccord Genuity Group

June 17 at 8:34 AM | marketbeat.com

After rebuffing Biogen, Sage pairs off with Supernus

June 17 at 12:27 AM | pharmaphorum.com

Supernus makes depression drug play with $795m Sage buyout

June 17 at 12:27 AM | msn.com

Sage, following Setbacks, to sell to Supernus for $561M

June 17 at 12:27 AM | biopharmadive.com

Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae

June 17 at 12:27 AM | fiercepharma.com

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus

June 17 at 12:27 AM | biospace.com

Sage Therapeutics gets acquired by Maryland drugmaker for up to $795 million

June 17 at 12:27 AM | bostonglobe.com

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.

June 17 at 12:27 AM | msn.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

June 16 at 5:31 PM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SAGE, HRMY, BEAM, and GLPG Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$16.99 +0.32 (+1.92%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$17.16 +0.17 (+0.99%)

As of 06/18/2025 07:56 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Galapagos NASDAQ:GLPG

$28.22 +0.30 (+1.07%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$28.22 0.00 (-0.02%)

As of 06/18/2025 07:42 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Harmony Biosciences NASDAQ:HRMY

$32.48 +0.01 (+0.03%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$32.48 0.00 (-0.02%)

As of 06/18/2025 04:20 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Sage Therapeutics NASDAQ:SAGE

$9.13 +0.01 (+0.11%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.18 +0.05 (+0.60%)

As of 06/18/2025 07:58 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time